Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 15/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 15/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.48 |
| ▸ | HRH2 | P25021 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | HTR5A | P47898 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21800290 | 0.89 | ABHD6 (0.55) | DHFRTMEM97SIGMAR1ADRA2AADRA2B | |
| SCHEMBL13984116 | 0.88 | DHFR (0.66) | DHFRTMEM97SIGMAR1KDRADRA2A | |
| SCHEMBL31173430 | 0.84 | DHFR (0.58) | DHFRTMEM97SIGMAR1KDRADRA2A | |
| SCHEMBL11091799 | 0.84 | DHFR (0.60) | DHFRTMEM97SIGMAR1KDRADRA2A | |
| SCHEMBL31091972 | 0.84 | DHFR (0.60) | DHFRTMEM97SIGMAR1KDRADRA2A | |
| SCHEMBL28506393 | 0.81 | DHFR (0.57) | DHFRTMEM97SIGMAR1KDRADRA2A | |
| SCHEMBL30422312 | 0.81 | DHFR (0.54) | DHFRTMEM97SIGMAR1 | |
| SCHEMBL26752181 | 0.80 | PTGDR2 (0.55) | DHFRKDRMEN1KMT2A | |
| SCHEMBL29934061 | 0.80 | DHFR (0.67) | DHFRTMEM97SIGMAR1KDRADRA2A | |
| SCHEMBL21956030 | 0.79 | ABHD6 (0.44) | DHFRTMEM97SIGMAR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| EP-4572761-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| CN-119730854-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-11952363-B2 | Piperazine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2024038129-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| EP-3807270-B1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-09-13 | — | — | EP | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210300947-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-09-30 | — | — | US | disclosed |
| CN-112313228-A | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE7A | DHFR 1220/4885TMEM97 3721/4885SIGMAR1 1342/4885 |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | SSB, UACA, HLA-DRB1 | DHFR 1078/4885TMEM97 4357/4885SIGMAR1 4247/4885 |
| US-20210300947-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, UACA, HLA-DRB1 | DHFR 1619/4885TMEM97 4195/4885SIGMAR1 4238/4885 |
| US-11952363-B2 | Piperazine compounds for the treatment of autoimmune disease | SSB, HLA-DRB1, IL5 | DHFR 480/4885TMEM97 2377/4885SIGMAR1 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.